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Memory loss characterizes several neurodegenerative disorders, including Alzheimer’s disease (AD). 
Inhibition of type 4 phosphodiesterase (PDE4) and elevation of cyclic adenosine monophosphate 
(cAMP) has emerged as a promising therapeutic approach to treat cognitive deficits. However, PDE4 
exists in several isoforms and pan inhibitors cannot be used in humans due to severe emesis. Here, we 
present GEBR-32a, a new PDE4D full inhibitor that has been characterized both in vitro and in vivo using 
biochemical, electrophysiological and behavioural analyses. GEBR-32a efficiently enhances cAMP in 
neuronal cultures and hippocampal slices. In vivo pharmacokinetic analysis shows that GEBR-32a is 
rapidly distributed within the central nervous system with a very favourable brain/blood ratio. Specific 
behavioural tests (object location and Y-maze continuous alternation tasks) demonstrate that this 
PDE4D inhibitor is able to enhance memory in AD transgenic mice and concomitantly rescues their 
hippocampal long-term potentiation deficit. Of great relevance, our preliminary toxicological analysis 
indicates that GEBR-32a is not cytotoxic and genotoxic, and does not seem to possess emetic-like side 
effects. In conclusion, GEBR-32a could represent a very promising cognitive-enhancing drug with a 
great potential for the treatment of Alzheimer’s disease.
Memory loss characterizes several neurodegenerative pathologies among which Alzheimer’s disease (AD) cer-
tainly represents the most common form of dementia. At present, cognitive disorders cannot benefit from effec-
tive therapies which are urged, given their socioeconomic impact that is expected to increase dramatically in the 
near future.
Over the last 30 years, neuroscience research has consistently demonstrated that cyclic adenosine monophos-
phate (cAMP) and its downstream effectors play a pivotal role in the molecular mechanisms underlying memory 
formation1. Indeed, pharmacological and genetic manipulations aimed at stimulating the cAMP pathway have 
been shown to enhance cognition under physiological conditions and, more importantly from a translational 
point of view, to normalize memory in different experimental models of cognitive impairment, including trans-
genic AD animals.
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At the cellular level, it is generally accepted that the pro-cognitive properties of cAMP are due to its key func-
tion in the expression of long-term potentiation (LTP), a form of synaptic plasticity that is considered the elec-
trophysiological correlate of memory2. As a matter of fact, knockout of adenylyl cyclase, the cAMP-synthesizing 
enzyme, significantly impairs LTP and memory formation3, whereas its overexpression does the opposite4,5. 
Similarly, stimulation or blockade of the cAMP effectors protein kinase A (PKA), Exchange Protein Directly 
Activated by cAMP (EPAC) and cAMP Responsive Element Binding Protein (CREB), respectively facilitates or 
disrupts LTP and memory6–17.
A large body of evidence also indicates that inhibition of the phosphodiesterase (PDE)-mediated hydroly-
sis of cAMP could represent a successful therapeutic strategy to treat memory deficits. Among the 11 different 
PDEs, the type 4 family (PDE4) has been identified as one of the most promising target for the treatment of 
cognitive-related disorders18–22.
The PDE4 family comprises four isoforms (PDE4A-D), but pan-PDE4 inhibitors, such as rolipram, albeit 
being effective pro-cognitive drugs in pre-clinical settings, are endowed with severe undesired side effects (i.e. 
emesis) that have hampered their clinical use23.
Recently, PDE4D has emerged as a specific molecular target to develop selective inhibitors having positive 
effects on memory and improved side-effect profile24. In this context, our group has recently synthesized and 
characterized several selective PDE4D full inhibitors, some of which showed cognitive-enhancing properties in 
rodents at doses that were devoid of emetic-like effects25–30.
In line with lead optimization processes, we here report the development of the novel PDE4D full inhibitor 
GEBR-32a, a compound that exhibits improved brain and cell penetration and that is able to efficiently increase 
cAMP levels, to rescue impaired hippocampal LTP and to improve memory function in normal and AD mice. 
Importantly, GEBR-32a has no cytotoxic or genotoxic potential and does not evoke emetic-like effects.
Results
Synthesis and enzymatic profile of GEBR-32a. GEBR-32a was designed by our group as a fluorinated 
derivative of the lead compound 8a30 (Fig. 1). The 4-(difluoromethoxy)-3-hydroxybenzaldehyde, a key interme-
diate for GEBR-32a synthesis, was prepared using a novel microwave assisted procedure29 with improved yield 
with respect to other protocols reported in the literature.
GEBR-32a selectivity was evaluated on a panel of 20 recombinant human PDE isoforms and variants. At the 
concentration of 10 μ M, GEBR-32a was devoid of any significant activity toward PDE1B, 2A3, 4A4,B2, 5A1, 7A,B, 
8A1,B1, 9A1, 10A1 and 11A1, whereas it showed some inhibitory effect on PDE4A1,B1,B3 (Table 1).
On the other hand, our compound was very active on all the PDE4D variants analysed (Table 1) that were 
inhibited by more than 50%. The calculated IC50s of GEBR-32 towards those variants ranged from 1.16 to 4.97 μ 
M (Table 2).
Effect of GEBR-32a on intracellular cAMP levels. When neuronal HTLA cells were treated with 
GEBR-2a (100 μ M), a 2.5 fold increase of cAMP was observed with respect to controls, and a more marked effect 
was measured in the presence of the adenylyl cyclase activator forskolin (1 μ M) (Fig. 2a).
In rat hippocampal slices, GEBR-32a (0.1–100 μ M) was able to increase the forskolin (0.1 μ M)-induced cAMP 
production with a 4-fold elevation observed at the highest concentration tested and an apparent EC50 of 1.80 μ 
M (Fig. 2b).
Safety and pharmacokinetic profile of GEBR-32a. In HTLA cells, lactate dehydrogenase release and 
the phosphorylation of the chromatin-bound histone HA2.X (a marker of DNA damage) were analysed to assess 
cyto- and genotoxicity, respectively. As shown in Fig. 3a,b, 24 hours of exposure to a single high concentration 
(100 μ M) of GEBR-32a did not produce any significant effect in both assays.
The emetic-like effects of GEBR-32a were investigated using the xylazine/ketamine-induced anaesthesia test, 
which indicated that the administration of GEBR-32a (0.003–3 mg/kg) did not significantly influence the dura-
tion of anaesthesia in adult mice (Fig. 3c). Under the very same experimental conditions, in our previous study 
the pan PDE4 inhibitor rolipram significantly shortened anaesthesia time already at 0.03 and 0.3 mg/kg26 (Fig. 3c).
As for the pharmacokinetic, GEBR-32a (10 mg/kg) was rapidly absorbed and distributed to the brain 
(Tmax = 20 min) and also rapidly eliminated with a half-life of approximately 1 h (Fig. 3d and Table 3). The brain to 
plasma AUC0-t ratio was 2.71, indicating a favourable brain penetration of our PDE4D inhibitor.
Effects of GEBR-32a in the object location task (OLT) in wild type and Tg2576 mice. Figure 4a 
reports the performance of adult WT mice in the OLT, following administration of vehicle or of GEBR-32a 
Figure 1. Chemical structure of compounds 8a and GEBR-32a. 
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(0.0003–0.01 mg/kg) with an inter-trial interval of 24 hours. With this long-time interval, vehicle-treated mice 
did not remember the disposition of the objects they had visited in the learning trial T1 and, therefore, they spent 
almost the same time in exploring the two objects during the test trial T2. Thus, their d2 index was not different 
from zero. On the contrary, when mice were treated with GEBR-32a at the dose of 0.003 mg/kg, 3 hours after the 
learning trial T1, they did recognize that one object had been moved from its original position and, during the 
test trial T2, they explored it for much more time than the object that had not been moved. Therefore, their d2 
index was different from zero.
Figure 4b summarizes the results in the OLT, following administration of GEBR-32a (0.001–0.3 mg/kg), 
but with an inter-trial interval of 1 hour. With this short-time interval, control aged WT animals (vehicle) with 
intact memory were able to remember the position of the two objects and, therefore, during the test trial T2 
they explored the moved object more than the unmoved one, thus showing a d2 index > 0. On the contrary, 
age-matched vehicle-treated Tg2576 mice did not. Administration of GEBR-32a to aged WT animals did not 
increase their normal discrimination capabilities, whereas Tg2576 mice showed a significant improvement in 
memory performance, the d2 index being higher than zero at the doses of 0.03 and 0.3 mg/kg.
Effects of GEBR-32a in the Y-maze continuous alternation task in wild type and Tg2576 
mice. The effects of GEBR-32a administration (0.0003–0.3 mg/kg) on Y-maze alternation performance in aged 
WT and Tg2576 mice are summarized in Fig. 5a. When treated with vehicle, both aged WT and transgenic mice 
did not show a performance significantly higher than chance level (50% alternations), indicating that under these 
test conditions they were not able to correctly remember the arms already visited. GEBR-32a significantly amelio-
rated the performance in control animals at all the doses tested (alternations always higher than 50%). Under the 
same conditions, GEBR-32a was not able to induce any improvement in Tg2576 mice. However, when the PDE4D 
PDE
GEBR-32a % 
inhibition Comparator % inhibition
PDE1B 10.7 74.4 (Sildenafil 10 μ M)
PDE2A3 NI 89.6 (BAY 60-7550 1 nM)
PDE4A1 41.0 66.5 (Rolipram 10 μ M)
PDE4A4 11.0 60.1 (Rolipram 10 μ M)
PDE4B1 41.6 78.6 (Rolipram 10 μ M)
PDE4B2 26.3 69.6 (Rolipram 10 μ M)
PDE4B3 39.4 68.6 (Rolipram 10 μ M)
PDE4D1 82.2 83.1 (Rolipram 1 μ M)
PDE4D2 87.8 70.8 (Rolipram 1 μ M)
PDE4D3 63.6 52.6 (Rolipram 1 μ M)
PDE4D5 67.3 58.0 (Rolipram 1 μ M)
PDE4D7 90.7 86.7 (Rolipram 1 μ M)
PDE5A1 4.97 74.9 (Sildenafil 100 nM)
PDE7A NI 78.6 (BRL-50481 10 μ M)
PDE7B 8.61 47.3 (Dipyridamole 50 μ M)
PDE8A1 NI 64.4 (Dipyridamole 50 μ M)
PDE8B1 23.5 57.4 (Dipyridamole 50 μ M)
PDE9A1 NI 92.7 (SB 36216 1 μ M)
PDE10A1 NI 90.7 (Papaverine 1 μ M)
PDE11A1 NI 91.0 (Dipyridamole 10 μ M)
Table 1.  Enzymatic profile of GEBR-32a. Inhibitory activity of GEBR-32a has been evaluated at the 
concentration of 10 μ M on 20 different recombinant human PDEs expressed in baculovirus. Percent inhibition 
of comparators (at appropriate concentrations) is also reported. NI = no inhibition. In bold, PDEs whose 
activity was inhibited more than 50% by GEBR-32a.






Table 2.  GEBR-32a potency towards PDE4D isoforms. GEBR-32a has been tested at five different 
concentrations (1nM-100 μ M) on human recombinant PDE4D isoforms expressed in baculovirus. IC50s have 
been obtained by non-linear regression analysis of the concentration-inhibition curves.
www.nature.com/scientificreports/
4Scientific RepoRts | 7:46320 | DOI: 10.1038/srep46320
inhibitor was chronically administered (0.03 mg/kg for up to 23 days), also the transgenic animals showed alter-
nations significantly higher than 50% (Fig. 5b), indicating amelioration of memory function.
Effect of GEBR-32a on hippocampal long-term potentiation in wild type and Tg2576 mice. As 
shown in Fig. 6, vehicle-treated Tg2576 mice displayed a significant LTP impairment in comparison with 
age-matched WT controls. In the latter, chronic GEBR-32a administration (0.03 mg/kg for 23 days) caused a clear, 
though not significant, enhancement of LTP in comparison with respective controls. Of great relevance, GEBR-
32a was able to rescue the LTP deficit of Tg2576 mice to the level of vehicle-treated WT animals.
Discussion
In this study, we present GEBR-32a, a novel PDE4D inhibitor deriving from the lead optimization process of 
compound 8a, which was recently synthesized and characterized in our laboratories30.
A key strategy in modern drug design is to optimize absorption, distribution, metabolism and excretion 
(ADME) before a drug enters the clinical phase. In particular, drugs designed for neurodegenerative disorders 
need to readily cross the blood-brain barrier (BBB) in order to reach their targets. In pharmaceutical chemistry, 
introduction of fluorine atoms represents a common strategy to improve drug potency and optimize ADME 
parameters31–34. Actually, the number of fluorinated drugs approved by FDA and EMA has greatly increased over 
the last decade35. Fluorine substitution influences different aspects of drug-target interaction, as well as of ADME, 
by modulating basic or acid molecule pKa, structure conformation, hydrophobic interactions, lipophilicity and 
interaction with metabolizing enzymes31–35.
Our selectivity analysis, carried out on a panel of 20 PDE isoforms and variants, has confirmed that GEBR-
32a is very active on PDE4D isoforms and its potency has been indeed improved in comparison to its parent 
compound 8a. For example, GEBR-32a showed an IC50 of 2.43 μ M toward PDE4D3, whereas that of compound 
8a was 7.60 μ M30. Fluorine introduction had even more dramatic effects on BBB permeability, the brain/plasma 
ratio being extremely improved from 0.76 for compound 8a to 2.71 for GEBR-32a. For comparison, this ratio for 
the well-known PDE4 inhibitors rolipram and roflumilast is 2 and 1, respectively36,37.
In addition, the presence of two fluorine atoms did not alter the ability of GEBR-32a to functionally inhibit 
PDE4D enzymes, as demonstrated by the significant elevation of intracellular cAMP levels observed in vitro, 
in both cultured cells and hippocampal slices (Fig. 2). Of note, 100 μ M GEBR-32a was able to cause a 12-fold 
increase of the forskolin-induced elevation of cAMP in cultured cells, while the same concentration of its parent 
compound 8a evoked only a 4-fold increase under the very same experimental conditions30, indicating a better 
cell membrane diffusion of the fluorinated derivative.
Although some natural occurring fluorine-containing molecules are highly toxic (e.g. sodium monofluoro-
acetate), it is now well known that introduction of fluorine into drugs does not necessarily confer toxicity and, 
on the contrary, may reduce the toxicity of parent compounds by preventing their metabolic bioactivation31,35. 
As a matter of fact, our preliminary toxicological screening demonstrated that GEBR-32a does not have either 
Figure 2. Effect of GEBR-32a on cAMP levels. (a) Quantification of cAMP in HTLA cells. Samples were pre-
treated for 10 min with GEBR-32a (32a; 100 μ M) or an equal volume of DMSO. Then, 1 μ M forskolin (FSK) was 
added, where indicated, for 20 min. The histogram shows the mean ± s.e.m. for three independent experiments; 
***P < 0.001 and *P < 0.05 vs vehicle treated cells; ###P < 0.001 vs FSK alone (ANOVA and post hoc Newman-
Keuls test. (b) Quantification of cAMP in rat hippocampal slices. Slices (n = 7 per condition) were pre-treated 
with increasing amount of GEBR-32a (32a) for 15 min and then stimulated with 0.1 μ M forskolin for 15 min. 
The histogram shows the mean ± s.e.m. for six independent experiments; *P < 0.05 and **P < 0.01 vs samples 
receiving forskolin alone (ANOVA and post hoc Dunnett’s test).
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Figure 3. Safety and pharmacokinetic profile of GEBR-32a. (a) Cytotoxic potential of GEBR-32a (32a;  
100 μ M) or DMSO (Veh), relative to the positive control (P.C.), in HTLA cells. Data represent the mean ± s.e.m. 
of three independent experiments. (b) Western blot analysis of γ -H2AX in HTLA cells treated for 24 h with 
100 μ M of the genotoxic compound etoposide (Eto), GEBR-32a (32a) or an equal volume of DMSO (Veh). The 
H2AX signals represent the internal loading control. The image shows cropped blots and is representative  
of three independent experiments all showing essentially similar results. (c) Ketamine/xylazine induced  
α 2-adrenoceptor-mediated anaesthesia test as a measure of emetic-like effect. GEBR-32a (n = 10–12 per group) 
or Rolipram (5–7 per group) were administered (s.c.) 15 min after the induction of anesthesia. Displayed are the 
mean times (± s.e.m.) the mice stayed anesthetized during every condition, relative to vehicle (Veh, set at 100%). 
Data for Rolipram have been redrawn from ref. 26. ***p < 0.001 vs vehicle (One-way ANOVA followed by 
Bonferroni’s comparison t-test). (d) Pharmacokinetic analysis of GEBR-32a. The graph shows the plasma/brain 
concentrations of GEBR-32 over time following the subcutaneous injection of a 10 mg/kg dose in BALB/c mice. 
Each point represents the mean (± s.e.m.) of three determinations.
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cytotoxic or genotoxic effects, even when cells were exposed to a high concentration of the drug (100 μ M) for 
24 hours (Fig. 3a,b).
As inhibition of PDE4D activity has been consistently shown to ameliorate memory formation26,28,30,38,39, 
GEBR-32a was trialled in two different behavioural tests, the object location task (OLT) and the Y-maze alter-
nation task. To verify that fluorine introduction had not influenced the pro-cognitive properties of the parent 
compound 8a in normal adult mice30, we tested GEBR-32a under the same experimental conditions.
The OLT is used to assess episodic-like spatial memory by evaluating if mice recognize/remember that one 
of two objects, explored in the learning trial, has been moved to a different position in the test trial. In this case, 
vehicle-treated adult mice did not remember the spatial arrangement of the objects when tested in the OLT with 
an inter-trial delay of 24 hours, due to natural forgetting (Fig. 4a). On the contrary, when mice were treated with 
GEBR-32a, at a very low dose (0.003 mg/kg) three hours after the learning trial, a time point at which PDE4 
inhibitors specifically improve memory consolidation40, they were able to remember that one object was not in 
the same position as in the learning trial and, consequently, spent much more time in exploring it in the test trial 
(d2 index > 0). Therefore, GEBR-32a is indeed able to improve consolidation of spatial long-term memory 3 h 
after learning.
However, the observation that a drug improves cognition in normal animals, although of interest for drug 
development, has limited relevance from a translational point of view. For this reason, we further analysed the 
memory-enhancing properties of GEBR-32a on aged Tg2576 mice that are widely used to model Alzheimer’s 
dementia. When these mice are 9–12 months old, they show ß-amyloid plaque accumulation in brain tissue and 
synaptic and memory deficits41.
In these experiments, we evaluated the effects of GEBR-32a in the OLT with a 1-hour inter-trial interval, 
which allows normal animals to retain the information acquired during the learning trial. In this paradigm, in 
fact, vehicle-treated aged WT mice showed well-functioning short-term spatial memory (Fig. 4b), as they iden-
tified that one object had been moved from its original position and, therefore, they explored it for more time 
(d2 index > 0). For this reason, administration of GEBR-32a had no effects on their performance, as short-term 
Parameters Plasma Brain
Cmax (ng/ml) 993 2608
Tmax (h) 0.33 0.33
AUC0-t (ng·h/ml) 861 2330
t1/2 (h) 0.95 0.95
AUC0-t Ratio (Brain/Plasma) 2.71
Table 3.  Main pharmacokinetic parameters of GEBR-32a. GEBR-32a was administered subcutaneously 
to mice at the dose of 10 mg/kg. Blood samples and brain tissues were collected at 7 different time points and 
analysed for GEBR-32a content. The main pharmacokinetic parameters were calculated by non-compartmental 
analysis. Cmax: the maximum observed plasma/brain concentration; Tmax: the time corresponding to Cmax; 
AUC0-t: the area under the plasma/brain concentration versus time curve from time 0 to the last time point; t1/2: 
elimination half-life.
Figure 4. Acute administration of GEBR-32a improves memory consolidation in the object location test. 
The figure reports the d2 index (see Methods) measured under different experimental conditions. (a) GEBR-32a 
(32a) or vehicle (Veh) were administered to healthy adult mice 3 hours after the learning trial T1 and the test 
trial T2 was performed 24 hours after T1. d2 index is reported in the figure. Each bar represents mean  
(± s.e.m.) of 22–24 mice. ###P < 0.0001 vs. zero (chance level; one-sample t-test); ***P < 0.001 vs. vehicle (post-
hoc; Dunnett’s test). (b) GEBR-32a or vehicle were administered to aged WT or Tg2576 mice 30 min before the 
learning trial T1 and the test trial T2 was performed 1 hour after T1. Each bar represents mean (± s.e.m.) 13–16 
mice. *P < 0.05, **P < 0.01, ***P < 0.001 vs. zero (chance level; one-sample t-test).
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memory cannot be further improved probably due to ceiling effect. On the contrary, a memory impairment was 
evident in vehicle-treated Tg2576 mice, which were unable to distinguish the moved object and their d2 index 
was, in fact, not different from zero. Of great relevance, when these transgenic mice were acutely treated with 
GEBR-32a, they showed a relevant improvement of their short-term memory performance, exploring the moved 
object for more time during the test trial.
The Y-maze continuous alternation task analyses spatial working memory by measuring the number and the 
order of entries of mice into the three different arms of the maze. In this case, a 50% alternation is considered 
chance level and reflects the absence of working memory performance. Indeed, adult WT mice had a perfor-
mance compatible with intact working memory (alternations higher than 50%), which was not further improved 
by GEBR-32a administered 30 min before the trial (ceiling effect; data not shown). On the other hand, both aged 
WT and Tg2576 mice manifested memory impairment, since they scored alternations not different from chance 
level when treated with vehicle (Fig. 5a). When GEBR-32a was acutely administered 30 min before the test, aged 
WT mice had a significant memory improvement, whereas aged Tg2576 mice had not, suggesting that an acute 
increase of cAMP is not sufficient to ameliorate this type of cognitive deficit in this mouse model of Alzheimer’s 
disease. However, if chronically treated with GEBR-32a, also Tg2576 mice performed significantly better than 
chance levels. These results demonstrate that the impaired working memory can be recovered by a chronic treat-
ment with the selective PDE4D inhibitor.
In the attempt to correlate GEBR-32a memory-enhancing properties with cellular/molecular mechanisms, 
we investigated the effects of GEBR-32a on hippocampal long-term potentiation (LTP). Hippocampal LTP is a 
form of synaptic plasticity that is generally accepted to represent the molecular substrate of memory formation 
and is known to require a fine tuning of the cAMP/PKA/CREB pathway to function24. Moreover, a large body of 
evidence has shown that PDE4 inhibitors are able to rescue compromised LTP in different models of pathological 
conditions, including AD42,43.
Using GEBR-32a, we demonstrate for the first time that chronic inhibition of PDE4D is able to rescue the LTP 
deficit that is observed in Tg2576 mice (Fig. 6). This supports the notion that, among the different PDE4 isoforms, 
PDE4D is critically involved in plasticity, learning and memory processes21,44.
Figure 5. Acute and chronic effects of GEBR-32a in the Y-maze continuous alternation test. The figure 
reports the average percentage of alternations (see Methods) measured under different experimental conditions. 
(a) GEBR-32a (32a) or vehicle (Veh) were acutely administered to aged WT or Tg2576 mice 30 min before the 
trial. Each bar represents mean (± s.e.m.) of 5–10 mice. *P < 0.05, **P < 0.01, ***P < 0.001 vs. 50% alternations 
(chance level; one-sample t-test). (b) GEBR-32a was administered chronically (s.c.) for up to 23 days before the 
trial. Each bar represents mean (± s.e.m.) of 9–10 mice. **P < 0.01 vs 50% alternations (chance level; one-sample 
t-test).
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To date, the serious emesis associated with non isoform-selective PDE4 inhibitors has impeded their clini-
cal exploitation as promnesic drugs in those pathologies, such as AD, characterized by memory loss. Although 
rodents cannot vomit, it has been shown that preliminary screening for emetic-like potential of PDE4 inhibitors 
can be reliably carried out in these animals using the xylazine/ketamine-induced anaesthesia test45. It has been 
proposed that PDE4 inhibitors cause emesis by activating a sympathetic pathway through antagonism of presyn-
aptic α 2-adrenergic receptors, a hypothesis supported by the evidence that α 2-adrenergic antagonists stimulate 
vomiting, while clonidine, a selective α 2-receptor agonist, is able to prevent PDE4 inhibitor-induced emesis. In 
addition, α 2-adrenergic antagonists, as well as PDE4 inhibitors, reduce the time of anaesthesia induced by a xyla-
zine/ketamine mixture45,46. Using this test, we have recently confirmed that rolipram is able to reduce the anaes-
thesia time at the same dose improving memory in mice26. On the contrary, our initial hits26,30 and our optimized 
lead GEBR-32a (Fig. 3c) are ineffective on anaesthesia time at doses 100–1000 times higher than the pro-cognitive 
ones, thus indicating that they are very likely devoid of emetic side-effects.
Therefore, the memory-improving effects of GEBR-32a are further dissociated from possible emetic-like 
effects, as compared to its parent compound 8a. A possible explanation could be that GEBR-32a (as 8a) inhibits 
PDE4D isoforms involved in memory processes per se. As for inhibition mechanisms, our relatively high IC50 
values reflect binding of GEBR-32a to the catalytic domain, yet interactions outside the catalytic domain cannot 
be ruled out, resulting in more or less selectivity for specific PDE4D isoforms. Clearly, more research is needed 
into this aspect, including co-crystallization of GEBR-32a and PDE4D isoforms to elucidate their interactions. 
Moreover, we need to know which specific PDE4D isoform to target for the treatment of memory decline in 
Alzheimer’s disease47.
As for the molecular mechanisms underlying the pro-cognitive effects of GEBR-32a in AD mice, it can be 
hypothesised that our PDE4D inhibitor reverses the Aβ -mediated inhibition of the cAMP/PKA/CREB pathway, 
as it happens with rolipram42,48, thus leading to the rescue of hippocampal LTP and memory deficits. Moreover, it 
has been reported that PDE4 inhibition can also reduce neuroinflammation by dampening the production of the 
proinflammatory cytokines IL-1b and TNFα and by increasing the levels of TGFβ -1 and BDNF, which are known 
to play a key role in hippocampal synaptic plasticity and memory49–51.
In conclusion, GEBR-32a is a selective PDE4D inhibitor endowed with a very favourable toxicological and 
pharmacokinetic profile, and is able to improve spatial memory processes without undesired emetic-like side 
effects. Although further safety studies are needed, GEBR-32a is a promising therapeutic agent for the treatment 
of cognitive decline in AD and related dementias.
Methods
Synthesis and enzymatic profile of GEBR-32a. Figure 7 reports the synthesis of GEBR-32a. We pre-
pared the starting product 4-(difluoromethoxy)-3-hydroxybenzaldehyde (1) using our recently reported micro-
wave assisted procedure with improved yield in comparison to many other procedures reported in the literature29. 
The 3-(cyclopentyloxy)-4-(difluoromethoxy)benzaldehyde (2) was then obtained by alkylation with bromocyclo-
pentane in anhydrous N,N-dimethylformamide (DMF), in the presence of potassium carbonate and potassium 
iodide [A. Thomas et al. PCT Int. Appl., 2004, WO 2004016596]. Then, we prepared the 3-[3-(cyclopentylox-
y)-4-(difluoromethoxy)phenyl]-1H-pyrazole (3) by one-pot 1,3-dipolar cycloaddition between the benzaldehyde 
Figure 6. Chronic administration of GEBR-32a rescues hippocampal long-term potentiation deficits in 
Tg2576 mice. WT and Tg2576 mice were treated with vehicle (Veh) or GEBR-32a (32a; 0.03 mg/kg) for 23 days. 
Electrophysiological recordings of field excitatory post-synaptic potentials (fEPSP) have been carried out on 
fresh hippocampal slices obtained from the respective mice and are reported in the figure as percentage of the 
mean baseline value (defined 100%) that was determined by averaging the recordings of the first 30 min. LTP 
was evoked as reported in the Methods. Each point represents mean (± s.e.m.). Statistical analysis demonstrated 
that Tg2576 mice exhibited a significant impairment in comparison to aged-matched WT mice (2 hours 
LTP: WT veh vs. Tg2576 veh F1,18 = 4.942, p = 0.0393; last 10 min LTP: WT veh vs. Tg2576 veh F1,18 = 5.672, 
p = 0.0285). Chronic treatment with GEBR-32a was able to significantly restore normal LTP in Tg2576 mice 
(2 hours LTP: Tg2576 veh vs. Tg2576 32a F1,18 = 3.651, P = 0.0721; last 10 min LTP: Tg2576 veh vs. Tg2576 32a: 
F1,18 = 6.014, P = 0.0246).
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(2) and p-toluenesulfonyl hydrazide, and subsequent addition of NaOH and 1-vinylimidazole in acetonitrile. The 
pyrazole intermediate (3) was then treated with an excess of epichlorohydrin in the presence of TEA to obtain the 
3-[3-(cyclopentyloxy)-4-(difluoromethoxy)phenyl]-1-(oxiran-2-ylmethyl)-1H-pyrazole (4) as a single isomer. 
Finally, GEBR-32a was obtained by reacting the oxirane (4) with an excess of morpholine.
Synthesis of 3-[3-(cyclopentyloxy)-4-(difluoromethoxy)phenyl]-1H-pyrazole. A solution of 3-(cyclopentylox-
y)-4-(difluoromethoxy)benzaldehyde 2 (1.65 g, 6.45 mmol) in anhydrous acetonitrile (2 mL) was added to 
p-toluenesulfonyl hydrazide (1.2 g, 6.45 mmol) solved in anhydrous acetonitrile (7 mL) and the mixture was 
stirred at room temperature for 1 h. Then, 5 N NaOH solution (1.29 mL, 6.45 mmol) was added and the mixture, 
which became coloured in red, was stirred at room temperature for 20 min. Afterward, 1-vinylimidazole (3.04 g, 
32.25 mmol, 2.92 mL) was slowly added and the mixture was heated at 50 °C for 48 h. After cooling to room tem-
perature, the solvent was removed under reduced pressure and the crude was solved in ethylacetate (10 mL). The 
organic phase was washed with brine (2 × 10 mL), 1 N HCl solution (10 mL), water (3 × 10 mL), dried (MgSO4), 
and concentrated under reduced pressure to afford a light yellow oil which was purified by silicagel (100–200 
mesh) column chromatography using CH2Cl2 as eluent. The pure product was obtained as a light yellow oil. Yield: 
45%. 1H-NMR (CDCl3): δ1.52–1.94 (m, 8H, 4CH2 cyclopent.), 4.80–5.00 (m, 1H, OCH cyclopent.), 6.55–7.70 
(m, 7H, 3H Ar + H-5 pyraz. + H-4 pyraz + OCHF2 + NH pyraz.). Anal. (C15H16N2O2F2) C, H, N. (% calculated/
found) C: 61.22/61.32; H: 5.48/5.71; N: 9.52/9.59.
Synthesis of 3-[3-(cyclopentyloxy)-4-(difluoromethoxy)phenyl]-1-(oxiran-2-ylmethyl)-1H-pyrazole. A mixture 
of 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1H-pyrazole 3 (1.3 g, 4.42 mmol) and epichlorohydrin (4.5 mL, 
57.77 mmol) was cooled at 5 °C. Afterward, TEA (6.63 mmol, 0.92 mL) was added dropwise and the reaction mix-
ture was stirred until the temperature became 25 °C. Then, the mixture was heated at 70 °C for 6 h. After cooling 
to room temperature, the mixture was poured into water (100 mL), the aqueous phase was extracted with CH2Cl2 
(2 × 20 mL). The organic phase was washed with water (20 mL), until the pH of the washing solution became neu-
tral, and with brine (3 × 20 mL). It was, then, dried (MgSO4) and concentrated under reduced pressure, yielding 
an oil that was purified by silicagel (100–200 mesh) column chromatography using diethyl ether as eluent. The 
pure product was obtained as a light yellow oil. Yield: 58%. 1HNMR (CDCl3): δ1.58–2.04 (m, 8H, 4CH2 cyclo-
pent.), 2.53–2.61 (m, 1H, HA of CH2 epox.), 2.83–2.94 (m, 1H, HB of CH2 epox.), 3.36–3.48 (m, 1H, CHO epox.), 
4.13–4.28 and 4.52–4.65 (m, 2H, CH2N pyraz), 4.93–5.03 (m, 1H, OCH cyclopent.), 6.56 (d, J = 2.4 Hz, 1H, H-4 
pyraz.), 6.58 (t, J = 75.6, 1H, OCHF2), 7.19 (d, J = 8.0 Hz, 1H, H-5 Ar), 7.29 (dd, J = 8.0, 2.0 Hz, 1H, H-6 Ar), 7.48 
(d, J = 2.0 Hz, 1H, H-2 Ar), 7.53 (d, J = 2.4 Hz, 1H, H-5 pyraz.). Anal. (C18H20N2O3F2) C, H, N. (% calculated/
found) C: 61.71/61.86; H: 5.75/5.99; N: 8.00/8.07.
Synthesis of 1-{3-]3-(cyclopentyloxy)-4-(difluoromethoxy)phenyl]-1H-pyrazol-1-yl}-3-morpholin-4-ylpropan-2-ol 
(GEBR-32a). An excess of morpholine (1 mL) was added to 3-[3-(cyclopentyloxy)-4-(difluoromethoxy)phe-
nyl]-1-(oxiran-2-ylmethyl)-1H-pyrazole 7 (0.37 g, 1.06 mmol) and the mixture was heated at 50–60 °C for 18 h. 
After cooling to room temperature, the mixture was diluted with diethyl ether (20 mL), then the organic phase 
was washed with water (20 mL), dried (MgSO4) and concentrated under reduced pressure. The crude was purified 
by silicagel (100–200 mesh) column chromatography using, as eluents, diethyl ether first and then a mixture of 
CH2Cl2/CH3OH (9:1) to obtain the pure product as light yellow oil.
Yield: 56%.1H-NMR (CDCl3): δ1.60–2.07 (m, 8H, 4CH2 cyclopent.), 2.44–2.84, 3.63–3.93 (2 m, 10H, 4CH2 
morph. + CH2N), 4.13–4.40 (m, 3H, CH2N pyraz. + CH-OH), 4.82–4.92 (m, 1H, OCH cyclopent), 6.54 (d, J = 2.4, 
1H, H-4 pyraz.), 6.58 (t, J = 75.6 Hz, 1H, OCHF2), 7.18 (d, J = 8.0 Hz, 1H, H-5 Ar), 7.28 (d, J = 8.0 Hz, 1H, H-6 
Ar), 7.44 (s, 1H, H-2 Ar), 7.56 (d, J = 2.4, 1H, H-5 pyraz.). IR (CHCl3) cm−1: 3413 (OH). Anal. (C22H29N3O4F2) C, 
H, N. (% calculated/found) C: 60.40/60.40; H: 6.68/6.81; N: 9.61/9.24.
Figure 7. Synthesis of GEBR-32a. Reagents and Conditions: a) CClF2COOCH3, Cs2CO3, anydrous DMF, 
300 W, 90 °C, 25 min., yield 57%; b) bromocyclopentane, K2CO3/KI, an. DMF, 65 °C, 22 h, yield 87%; c) 
p-toluenesulfonyl hydrazide, anhydrous acetonitrile, RT, 1 h; 5N NaOH solution RT, 20 min.; 1-vinylimidazole, 
50 °C, 48 h, yield 45%; d) epichlorohydrin 0–5 °C; then, TEA, stirred until 25 °C, then 70 °C, 6 h, 58%; e) 
morpholine excess, 50–60 °C, 18 h, yield 56%. 
www.nature.com/scientificreports/
1 0Scientific RepoRts | 7:46320 | DOI: 10.1038/srep46320
All chemicals were purchased from Chiminord and Aldrich Chemical (Milan, Italy). Solvents were reagent 
grade. Unless otherwise reported, all commercial reagents were used without any further purification. Aluminium 
backed silica gel plates (Merck DC-Alufolien Kieselgel 60 F254, Darmstad, Germany), were used in thin-layer 
chromatography (TLC) for routine monitoring the course of reactions. Detection of spots was made by UV light. 
Merck silica gel, 230–400 mesh, was used for chromatography.
Melting points are not “corrected” and were measured with a Buchi M-560 instrument. IR spectra were 
recorded with a Perkin-Elmer 398 spectrophotometer. 1H NMR spectra were recorded on a Varian Gemini 200 
(200 MHz) instrument, chemical shifts are reported as δ (ppm) relative to tetramethylsilane (TMS) as internal 
standard; signals were characterized as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br s (broad 
signal); J in Hz. Elemental analyses were determined with an elemental analyzer EA 1110 (Fison-Instruments, 
Milan, Italy) and the purity of all synthesized compounds was > 95%.
The enzymatic profile of GEBR-32a has been carried out by Scottish Biochem (Glasgow, Scotland, UK), using 
recombinant human PDE4 enzymes expressed in baculovirus, as previously reported25. In a first assay, GEBR-32a 
was preliminary tested at a single concentration (10 μ M) in duplicate on a panel of 20 PDE isoforms and variants; 
then, IC50 values were determined only for those PDEs whose inhibition by 10 μ M GEBR-32a was more than 
50%. The compound was tested at five different concentrations (1 nM to 100 μ M) and the IC50s were obtained by 
non-linear regression analysis of the concentration-inhibition curves (GraphPad Prism software).
Animals. C57BL/6J mice were supplied by Charles River (Sulzfeld, Germany) to Maastricht University. 
Tg2576 and wild type (WT) mouse colonies were maintained in the animal facilities of the Columbia University. 
The correct genotype was identified by PCR on tail samples. Adult Sprague-Dawley rat colony was maintained 
in the animal facilities of the Department of Pharmacy, University of Genoa. Only male animals were used in the 
experiments.
For behaviour experiments, adult (3–4 months of age) WT, aged WT and Tg2576 mice (12–21 months of age) 
were housed individually on a reverse light/dark cycle (light from 19:00 to 07:00). Rats were housed on a regular 
light/dark cycle (light from 07:00 to 19:00). Animals were kept at constant temperature (22 ± 1 °C) and relative 
humidity (50%) with free access to food and water.
All the respective experimental procedures have been approved by the IACUC Ethics Committee of Columbia 
University (USA), the Ethics Committee of Maastricht University (NL) and the Italian Ministry of Health for the 
University of Genoa (IT). All animal experiments have been carried out in accordance with the EU Directive 
2010/63/EU for animal experiments and the National Institutes of Health guide for the care and use of Laboratory 
animals (NIH Publications No. 8023, revised 1978). All efforts were made to minimize animal suffering and to use 
the minimal number of animals to produce reliable results.
cAMP determination in cultured cells and hippocampal slices. The cells used in this study (human 
neuroblastoma cell line HTLA-230, HTLA) were grown in Roswell Park Memorial Institute medium (RPMI), 
with 0.1 mM non-essential aminoacids and 10% fetal bovine serum. At the end of treatments, intracellular cAMP 
was measured with the DetectX® Direct Cyclic AMP Enzyme Immunoassay Kit (Arbor Assay, MI, USA), follow-
ing the manufacturer’s protocol.
Hippocampal slices (400 μ m thick) were obtained from adult Sprague Dawley rats using a McIlwain tissue 
chopper and pre-incubated in physiological medium52 (7 slices/condition) at 37 °C for 15 min, first with different 
concentrations of GEBR-32a and, then, with 0.1 μ M forskolin for further 15 min. Finally, slices were left in hot 
medium (90 °C) for 15 min, sonicated and centrifuged at 10000 g for 15 min. The supernatant was used for cAMP 
determination, using the same kit as above, and the pellet for protein quantification.
Results from cells and slices are presented as fold increase and represent mean ± S.E.M. of the number of 
experiments reported in the figure legend. Normal distribution was evaluated by Kolmogorov–Smirnov test and 
then data have been analysed by one-way ANOVA followed by Newman-Keuls or Dunnett’s tests, as appropriate.
Cytotoxicity and genotoxicity in cultured cells. For the cytotoxicity and genotoxicity assays, 
HTLA cells were treated for 24 hours with GEBR-32a (100 μ M) at 37 °C. At the end of the incubation period, 
lactate-dehydrogenase release was measured in conditioned media using the Cytoxicity Detection KitPLUS (Roche, 
Germany) according to manufacturer protocols.
To evaluate genotoxicity, cells were processed for total protein extraction as described previously53. 
Immunoblots were done according to standard methods, using the following antibodies: mouse monoclonal 
to gamma H2A.X (2F3, phospho S139) and rabbit polyclonal to Histone H2A.X (Abcam, UK); anti-mouse and 
anti-rabbit secondary antibodies coupled to horseradish peroxidase (GE Healthcare, UK). Proteins were vis-
ualized with an enzyme-linked chemiluminescence detection kit according to the manufacturer’s instructions 
(GE Healthcare). Chemiluminescence was monitored by exposure to films and signals were analyzed under 
non-saturating condition with an image densitometer (Bio-Rad, CA, USA).
Pharmacokinetic analysis. A total of 21 male BALB/c mice were used for each drug and three mice were 
used for each time point30. GEBR-32a was dissolved in DMSO, diluted in 0.5% methylcellulose to yield a final 
concentration of 1 mg/mL and administered subcutaneously at the dose of 10 mg/kg. Blood samples (approxi-
mately 250 μL) were collected via retro-orbital puncture into tubes containing sodium heparin at 10 min, 20 min, 
40 min, 1 h, 2 h, 3 h, and 5 h post-injection. Plasma was separated by centrifugation (11000 rpm, 5 min, 4 °C) and 
stored at −70 °C before analysis. After blood harvest, mice were sacrificed by cervical dislocation and brains were 
excised, weighed, rinsed by cold saline and then frozen at −70 °C until analysis.
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For blood analysis, 25 μL of plasma were transferred into a 1.5 mL Eppendorf tube and were added with 
25 μL of methanol and 25 μL of internal standard (500 ng/mL voriconazole), followed by the addition of 100 μL 
methanol.
As for brains, 100 mg of tissue were placed into a plastic tube and added with 500 μL of methanol to facilitate 
homogenization, which was carried out using a Fluko F6/10 superfine homogenizer for approximately 1 min. 
Homogenized samples were then treated by ultrasound for 10 min and centrifuged at 11000 rpm for 5 min. A 
25 μL aliquot of the homogenized samples was transferred into an Eppendorf tube and added with 20 μL of 
internal standard (500 ng/mL voriconazole) followed by the addition of 100 μL of methanol. After centrifugation 
at 11000 rpm for 5 min, a 5 μL aliquot (plasma or brain) was injected in a LC/MS/MS system (Shimadzu LC-20A 
HPLC system; AnaShiseido, Tokyo, Japan) coupled with a TSQ Quantum Vantage triple quadrupole mass spec-
trometer equipped with a HESI source (ThermoFisher, San Jose, CA, USA). Chromatographic conditions were 
the following: guard column SecurityGuard C18 column (4 mm × 3.0 mm I.D., 5 μ m, Phenomenex, Torrance, CA, 
USA), analytical column SB C18 (150 mm × 4.6 mm I.D., 5 μ m, Agilent, USA), buffers 0.1% formic acid in 10 mM 
ammonium acetate/0.1% formic acid in methanol (10:90), flow rate 0.6 mL/min. Mass spectrometric conditions 
were the following: source HESI, scan mode SRM, polarity positive, vaporizer temperature 420 °C, ion sweep 
gas pressure 1 bar, auxiliary gas pressure 5 bar, capillary temperature 320 °C. Calibration curves were prepared 
in heparinized blank mice plasma (3–3000 ng/mL) or blank brain homogenate (1–10000 ng/g). Concentrations 
were calculated using a weighted least-squares linear regression (W = 1/x2). The linear regression equations of the 
calibration curves are presented in the Table 4.
The main pharmacokinetic parameters were calculated by non-compartmental analysis using Phoenix 1.3 
(Pharsight USA).
AUC0-t: the area under the plasma/brain concentration versus time curve from time 0 to the last measurable con-
centration was calculated by using the linear trapezoidal rule.
Cmax: the maximum observed plasma concentration.
Tmax: the time corresponding to Cmax.
t1/2: the elimination half-life was calculated as 0.693/λ z. λ z was obtained by log-linear regression using the termi-
nal points of the plasma concentration-time curve.
Behavioural analysis. Drug preparation for behavioural testing. For all behavioural analysis, GEBR-32a 
was dissolved in dimethylsulfoxide (DMSO) and stored at 4 °C, this stock solution was used for further dilutions 
in 0.5% methylcellulose. The vehicle condition received 0.5% methylcellulose with 0.005% DMSO, and all drug 
solutions had a fixed percentage of 0.5% methylcellulose and 0.005% DMSO.
Object Location Task (OLT). The OLT has been derived from the Object Recognition Task (ORT)54. The appara-
tus consisted of a circular arena, 40 cm in diameter. The back half of the 40-cm high wall was made of grey poly-
vinyl chloride (PVC) and the front was made of transparent PVC. Fluorescent red tubes and a light bulb provided 
a constant illumination of about 20 lux on the floor of the apparatus. Two objects were placed in symmetrical 
positions at the mid-line between the black and transparent halves of the arena, about 5 cm away from wall. Four 
sets of 2 identical objects were used and these objects were presented to the animals in a balanced manner to avoid 
learning or place biases. The rodents were unable to displace the objects. Prior to the trials, mice were put in an 
empty cage for 4 minutes to increase arousal during testing. A test session comprised two 4-min trials. During 
the learning trial T1, the apparatus contained two identical objects placed on a horizontal line in the middle of 
the arena (object a1 and a2). The animals were always introduced into the apparatus with their nose towards the 
transparent wall segment (i.e. facing outwards to the front of the arena). Subsequently, the rodents were put back 
in their home cage for the inter-trial interval. After the retention interval, the animals were put back into the arena 
for the test trial T2, in which one object (a3) was in the same position as during T1 and the other (b) was moved 
to a different position to the front or back of the arena. The time spent exploring each object during T1 and T2 
was recorded manually on a personal computer. Exploration was defined in the following manner: directing the 
nose to the object at a distance of no more than 2 cm and/or touching the object with the nose. Sitting on the 
object was not considered as exploratory behaviour. In order to avoid the presence of olfactory cues, the objects 
were thoroughly cleaned with a 70% ethanol solution before each trial. Prior to compound testing, animals were 
handled for 5 minutes on 3 consecutive days and allowed to explore the arena for 5 min. Subsequently, animals 
were accustomed to the complete OLT testing procedure including injections prior or after testing. In a first set of 
experiments, GEBR-32a (0.0003–0.01 mg/kg s.c.) was evaluated in adult WT mice with a 24 h inter-trial interval 
and was administered 3 h after the first trial (T1) of the OLT40,55. Afterwards, it was tested (0.001–0.3 mg/kg s.c.) 
in memory deficit models (aged WT and Tg2576 mice) with a 1 hour inter-trial interval and was administered 
30 min before the first trial (T1) of the OLT. Of note, drug conditions were tested in semi-random order, so within 
one testing session, multiple treatment conditions were tested. The experimenter was blinded to the conditions 
that were being tested. Similar to the ORT, the readout parameters of the OLT are the time that rodents spent on 
exploring each object during T1 and T2. The exploration time (in seconds) of each object during T1 are presented 
Matrix Regression equations Correlation coefficient (r2)
Plasma y = 2.15 × 10−3 x + 2.16 × 10−3 0.9973
Brain y = 6.84 × 10−4 x + 4.87 × 10−4 0.9908
Table 4.  Calibration curves for GEBR-32a HPLC analysis. 
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as ‘a1’ and ‘a2’. The time spent in exploring the familiar and the moved objects in T2 are represented as ‘a3’ and ‘b’, 
respectively. Using these data, the following parameters were calculated: e1 = a1 + a2; e2 = a3 + b; d2 = (b–a3)/
e2. The d2 index is a relative measure of discrimination that corrects for exploratory activity56. The d2 index can 
range from -1 to 1. A significant positive difference from zero indicates that the mice remembered the object 
locations from T1. Of note, mice require a minimum amount of exploration in order to show reliable memory 
performance57. Therefore, animals were removed from the analysis if they spent less than 9 s exploring the objects 
during T1 or T2. Normal distribution of data was evaluated by Kolmogorov–Smirnov and one-way ANOVA was 
performed to evaluate differences between the conditions. A one sample t-test was used to compare the d2 index 
of the conditions to zero (i.e. chance level).
Y-maze continuous alternation task. The apparatus was made of grey Plexiglas with three arms symmetrically 
placed together at a 120° angle. At the beginning of the trial, each mouse was placed in one of three arms (ran-
domly divided and balanced) and was then allowed to freely explore the apparatus for 6 minutes. The number of 
entries into a different arm and the order was measured. An entry was only counted if all four paws of the animal 
were placed completely inside the arm. When a mouse visited all 3 arms consecutively, it made a triad. In between 
trials, the apparatus was cleaned with a 70% ethanol solution to avoid olfactory cues. In a first set of experiments, 
GEBR-32a (0.0003–0.3 mg/kg s.c.) was administered acutely to aged WT and Tg2576 mice 30 min before the trial. 
In a second set of experiments, GEBR-32a was administered chronically (23 days) at the dose of 0.003 mg/kg s.c. 
In order to reduce the number of animals necessary for experimentation and to increase statistical power, two 
testing sessions were performed (at day 22 and day 23) and combined. Of note, there was no statistical difference 
between testing sessions (day effect; data not shown) and, therefore, both test sessions were pooled. To measure 
spatial working memory, the percentage of alternations was calculated by taking the number of triads and divid-
ing it through the maximum possible alternations (total entries minus 2) and multiply this by 100. A score of 50% 
alternations is considered chance level and, therefore, a significant difference from 50% is indicative of functional 
working memory. Normal distribution of data was evaluated by Kolmogorov–Smirnov and one-way ANOVA 
was performed to evaluate differences between the conditions. For each condition, one-sample t-test was used for 
comparison versus the score of 50%.
Ketamine/xylazine induced α2-adrenoceptor-mediated anaesthesia test. To investigate possible emetic-like effect 
of GEBR-32a, mice were anesthetized with of 60 mg/kg ketamine and 10 mg/kg xylazine (i.p. injection, 1 ml/
kg). GEBR-32a (0.003–3 mg/kg) or vehicle were administered 15 minutes after the induction of anaesthesia and 
mice were put in dorsal position26. The outcome measurement was the total time the animals were anesthetized, 
measured from anaesthesia induction to the righting reflex (i.e. when mice were back on all four paws). In order 
to reduce the number of animals for experimentation and to get sufficient group sizes, the experiments were per-
formed three times with 2 recovery days in between. Each animal did not receive the same condition more than 
once, i.e per test day the drug treatments were balanced over the animals so each condition was tested in every 
animal eventually. Normal distribution of data was evaluated by Kolmogorov–Smirnov and one-way ANOVA was 
used to compare all conditions.
Electrophysiology recordings. Electrophysiological recordings have been carried out as previously 
described48. Briefly, hippocampal slices (400 μ M thick) were obtained from aged WT and Tg2576 mice, chron-
ically treated either with vehicle or with GEBR-32a (0.03 mg/kg s.c.), by means of a tissue chopper and subse-
quently were maintained under perfusion (1–3 ml/min) with saline solution (in mM: 124 NaCl, 4.4 KCl, 1.0 
Na2HPO4, 25.0 NaHCO3, 2.0 CaCl2, 2.0 MgSO4,10 glucose; continuously aerated with 95% O2 and 5% CO2) in 
an interface chamber at 29 °C for 90 min prior to recording. A concentric bipolar platinum-iridium stimulation 
electrode and a low-resistance glass recording microelectrode filled with saline solution (5 mΩ resistance) were 
placed in CA1 stratum radiatum to record the extracellular field excitatory postsynaptic potential (fEPSP). Basal 
synaptic transmission was assayed by plotting the stimulus voltages against slopes of fEPSP. For LTP experiments, 
a 15-min baseline was recorded every min at an intensity that evoked a response ~35% of the maximum response. 
LTP was induced using a θ -burst stimulation, consisting of 4 pulses at 100 Hz, with the bursts repeated at 5 Hz and 
each tetanus including three 10-burst trains separated by 15 s [33].
Normal distribution of data was evaluated by Kolmogorov–Smirnov test and two-way ANOVA was used to 
determine the rescuing effect of GEBR-32a on synaptic dysfunction.
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